A patient with acquired haemophilia A and pemphigus.
Haemophilia A is usually a genetic deficiency of coagulation factor VIII (F VIII). The development of antibodies against F VIII is a well known and frequent complication in the treatment of haemophilia A. Rarely, a F VIII inhibitor arises spontaneously, causing a condition which is known as acquired haemophilia A. We describe a patient with acquired haemophilia A and pemphigus, who presented with spontaneous haematomas of the extremities. Laboratory tests showed an activated partial thromboplastin time (aPTT) of 71 s (normal: 26-36 s), a F VIII concentration of 9% (normal: 60-140%), and a F VIII inhibitor-activity of 7.5 Bethesda Units/ml (B.U./ml, normal: 0). The haematomas disappeared within a few days and the laboratory tests normalized within 6 weeks, after administration of a booster of oral corticosteroids. One and a half years after the corticosteroids were stopped, both the clinical and the laboratory course of the patient has been uneventful. As far as we know, the combination of acquired haemophilia A and pemphigus has been reported in the literature only three times before. The diagnosis acquired haemophilia A should be considered in a patient presenting with a newly arisen haemorrhagic diathesis.
Halbertsma
F J
FJ
Kennemer Gasthuis, Department of Internal Medicine, Haarlem, Netherlands.
van der Linden
P W
PW
Mauser-Bunschoten
E P
EP
D000368:Aged; D005169:Factor VIII / Q000378:metabolism; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006406:Hematoma / Q000188:drug therapy / Q000209:etiology; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007866:Leg / Q000098:blood supply; D008297:Male; D010392:Pemphigus / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use
D005938:Glucocorticoids; D005169:Factor VIII; D011241:Prednisone